Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076801 | 0.86 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1TRPV1ROCK2TSHR | |
| SCHEMBL1642548 | 0.85 | TSHR (0.46) | ALDH1A1L3MBTL1TRPV1CYP3A4KDM4E | |
| SCHEMBL1643132 | 0.79 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1CYP3A4ROCK2TSHR | |
| SCHEMBL1644164 | 0.78 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1TRPV1CYP3A4ROCK2 | |
| SCHEMBL10533579 | 0.77 | CETP (0.47) | ALDH1A1L3MBTL1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL2081210 | 0.76 | NPC1 (0.43) | ALDH1A1TRPV1MAPTTSHRNPC1 | |
| SCHEMBL1643897 | 0.75 | KMT2A (0.40) | ALDH1A1L3MBTL1MAPTKDM4ETSHR | |
| SCHEMBL9846978 | 0.75 | TSHR (0.46) | ALDH1A1L3MBTL1TRPV1CYP3A4KDM4E | |
| SCHEMBL1642398 | 0.75 | TSHR (0.44) | ALDH1A1ROCK2KDM4ETSHRNPC1 | |
| SCHEMBL1643191 | 0.74 | KDM4E (0.46) | ALDH1A1MAPTKDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | ALDH1A1 2099/4885L3MBTL1 4231/4885TRPV1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.